American Heart Association Principles on the Accessibility and Affordability of Drugs and Biologics
Published: November 09, 2017
- Market entry prices of innovator pharmaceutical products, or brand drugs and biologics, are at levels some consider unaffordable and prices for some generic drugs have seen sharp, rapid increases. These troublesome trends warrant serious consideration by all healthcare stakeholders.
- The American Heart Association consistently has advocated for equity and affordability and will continue to pursue equitable access for all.
- To support patients in addressing rising drug costs and curtail the associated adverse health impacts, the AHA developed a set of principles to guide its advocacy and help frame the ongoing debate.